Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 5/20 | 0.59 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2175358 | 0.85 | KCNA5 (0.54) | KCNA5KCNH2CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL538512 | 0.84 | KMT2A (0.60) | PTGER1PTGER4PTGER3PTGER2AKR1B1 | |
| SCHEMBL3737503 | 0.83 | AKR1B1 (0.50) | KCNA5KCNH2PTGER1PTGER4PTGER3 | |
| SCHEMBL28594606 | 0.82 | KMT2A (0.58) | PTGER1PTGER4PTGER3PTGER2AKR1B1 | |
| SCHEMBL29512995 | 0.82 | KMT2A (0.58) | PTGER1PTGER4PTGER3PTGER2AKR1B1 | |
| Hydrochloric Acid SCHEMBL11895689 | 0.82 | KMT2A (0.58) | PTGER1PTGER4PTGER3PTGER2AKR1B1 | |
| Ammonia Solution, Strong SCHEMBL27926479 | 0.82 | KMT2A (0.58) | PTGER1PTGER4PTGER3PTGER2AKR1B1 | |
| SCHEMBL27701716 | 0.82 | KMT2A (0.58) | PTGER1PTGER4PTGER3PTGER2KDM4E | |
| SCHEMBL2555729 | 0.81 | KCNA5 (0.51) | KCNA5KCNH2CYP11B1CYP11B2KDM4E | |
| SCHEMBL14927055 | 0.81 | PTGS1 (0.47) | KCNA5NAPRTKCNH2KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255173-A1 | Novel Specific Caspase-10 Inhibitors | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-16 | — | — | US | claimed |
| EP-1817031-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | Merck Patent GmbH (DE) | 2007-08-15 | — | — | EP | claimed |
| WO-2006058592-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GMBH (DE) | 2006-06-08 | — | — | WO | claimed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-7829721-B2 | Specific caspase-10 inhibitors | MERCK PATENT GMBH (DE) | 2010-11-09 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20080255173-A1 | Novel Specific Caspase-10 Inhibitors | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1817031-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | Merck Patent GmbH (DE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006058592-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
| US-5962439-A | CARDIOVASCULAR DISORDER | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5849919-A | Fused benzeneoxyacetic acid derivatives which have PGI2 receptor anonist activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0548949-B1 | Fused benzeneoxyacetic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1997-09-17 | — | — | EP | disclosed |
| US-5589496-A | Fused benzeneoxyacetic acid derivatives which have PGI2 receptor agonist activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-12-31 | — | — | US | disclosed |
| US-5389666-A | Administering for treatment and prevention of thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer or hypertension | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0548949-A2 | Fused benzeneoxyacetic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255173-A1 | Novel Specific Caspase-10 Inhibitors | CASP10, CASP1, CASP5 | KCNA5 2023/4885NAPRT 4210/4885KCNH2 3252/4885 |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | KCNA5 1370/4885NAPRT 340/4885KCNH2 2070/4885 |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | KCNA5 3411/4885NAPRT 1081/4885KCNH2 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.